View ValuationGetinge 향후 성장Future 기준 점검 1/6Getinge (는) 각각 연간 10.4% 및 4.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.4% 로 예상됩니다.핵심 정보10.4%이익 성장률10.80%EPS 성장률Medical Equipment 이익 성장12.3%매출 성장률4.8%향후 자기자본이익률10.41%애널리스트 커버리지Good마지막 업데이트28 Jul 2026최근 향후 성장 업데이트공고 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.공고 • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.공고 • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.공고 • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.공고 • Jul 16Getinge AB Provides Sales Guidance for the Year 2021Getinge AB provided sales guidance for the year 2021. For 2021, the company estimates that sales will strengthen based on 2019's level to a minimum of SEK 27 billion as health care returns to normal capacity. In the long term, the company expects 2%-4% organic annual growth in net sales.모든 업데이트 보기Recent updatesReported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr3.09 (vs kr1.92 in 2Q 2025)Second quarter 2026 results: EPS: kr3.09 (up from kr1.92 in 2Q 2025). Revenue: kr8.38b (up 1.7% from 2Q 2025). Net income: kr841.0m (up 61% from 2Q 2025). Profit margin: 10.0% (up from 6.4% in 2Q 2025). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.공고 • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.공고 • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.공고 • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.공고 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026공고 • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.공고 • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.공고 • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).공고 • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.공고 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.공고 • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index공고 • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.공고 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025공고 • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.공고 • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden공고 • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.Recent Insider Transactions • Dec 31Independent Director recently bought €91k worth of stockOn the 23rd of December, Cecilia Wennborg bought around 6k shares on-market at roughly €15.20 per share. This transaction amounted to 48% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €909k. Insiders have collectively bought €2.3m more in shares than they have sold in the last 12 months.공고 • Dec 10+ 1 more updateGetinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025공고 • Nov 28Getinge AB (Publ) Announces Changes of the Nomination CommitteeGetinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson.공고 • Nov 09Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th.Reported Earnings • Oct 18Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)Third quarter 2024 results: EPS: kr0.007 (down from kr3.28 in 3Q 2023). Revenue: kr7.87b (up 3.5% from 3Q 2023). Net income: kr2.00m (down 100% from 3Q 2023). Profit margin: 0% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Sep 19Independent Director recently bought €98k worth of stockOn the 16th of September, Kristian Samuelsson bought around 5k shares on-market at roughly €19.56 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth €383k. Insiders have collectively bought €1.1m more in shares than they have sold in the last 12 months.공고 • Sep 13Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled.Recent Insider Transactions • Sep 05Independent Chairman recently bought €375k worth of stockOn the 3rd of September, Johan Malmquist bought around 20k shares on-market at roughly €18.74 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months.공고 • Aug 23Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.Reported Earnings • Jul 20Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)Second quarter 2024 results: EPS: kr1.88 (up from kr0.79 in 2Q 2023). Revenue: kr8.31b (up 16% from 2Q 2023). Net income: kr513.0m (up 140% from 2Q 2023). Profit margin: 6.2% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 20% per year.New Risk • Jul 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.9% average weekly change).공고 • Jul 01Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €16.30, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.91 per share.공고 • Apr 23Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024.Upcoming Dividend • Apr 16Upcoming dividend of kr4.40 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 29 April 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 28Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공고 • Mar 28+ 2 more updatesGetinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025Getinge AB (publ) announced that they will report fiscal year 2024 results on Jan 28, 2025Declared Dividend • Mar 25Dividend of kr4.40 announcedShareholders will receive a dividend of kr4.40. Ex-date: 23rd April 2024 Payment date: 29th April 2024 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (75% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Mar 16+ 1 more updateGetinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Getinge AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024공고 • Mar 15+ 1 more updateGetinge AB (Publ) Proposes Dividend, Payable on April 29, 2024Getinge AB (publ) at its Annual General Meeting to be held on April 22, 2024, board and the CEO have proposed that a dividend of SEK 4.40 per share shall be declared. As record date for the dividend, the Board proposes April 24, 2024. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting April 29, 2024.공고 • Mar 08Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.Reported Earnings • Feb 01Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.공고 • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.공고 • Jan 23Getinge Announces CFO ChangesLars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge.Reported Earnings • Oct 23Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr7.61b (up 9.6% from 3Q 2022). Net income: kr894.0m (up 12% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.공고 • Oct 12Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023.공고 • Sep 20Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023.Reported Earnings • Jul 19Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr7.18b (up 7.6% from 2Q 2022). Net income: kr214.0m (down 65% from 2Q 2022). Profit margin: 3.0% (down from 9.0% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 7% per year.공고 • Jul 08Getinge Receives US FDA 510(K) Clearance for Servo-Air® LiteGetinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €17.93, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 9.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.98 per share.공고 • Jun 01Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023. The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023.Reported Earnings • Apr 27First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr7.14b (up 16% from 1Q 2022). Net income: kr586.0m (up 9.7% from 1Q 2022). Profit margin: 8.2% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.Buying Opportunity • Apr 27Now 23% undervaluedOver the last 90 days, the stock is up 9.0%. The fair value is estimated to be €29.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 5.6%.Upcoming Dividend • Apr 20Upcoming dividend of kr4.25 per share at 1.6% yieldEligible shareholders must have bought the stock before 27 April 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%).공고 • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.Reported Earnings • Feb 02Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)Full year 2022 results: EPS: kr9.15 (down from kr10.90 in FY 2021). Revenue: kr28.3b (up 4.6% from FY 2021). Net income: kr2.49b (down 16% from FY 2021). Profit margin: 8.8% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.공고 • Feb 02Getinge AB (Publ) Proposes DividendGetinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00).Reported Earnings • Oct 21Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr6.94b (up 10% from 3Q 2021). Net income: kr798.0m (up 5.4% from 3Q 2021). Profit margin: 12% (in line with 3Q 2021). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Jul 20Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)Second quarter 2022 results: EPS: kr2.21 (down from kr2.93 in 2Q 2021). Revenue: kr6.67b (up 1.3% from 2Q 2021). Net income: kr603.0m (down 24% from 2Q 2021). Profit margin: 9.0% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €19.62, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 45% over the past three years.Recent Insider Transactions • May 01Independent Chairman recently bought €281k worth of stockOn the 28th of April, Johan Malmquist bought around 10k shares on-market at roughly €28.06 per share. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Apr 27Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022Getinge AB (publ) announced that In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.00 per share April 28, 2022 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting May 3, 2022.Upcoming Dividend • Apr 20Upcoming dividend of kr4.00 per shareEligible shareholders must have bought the stock before 27 April 2022. Payment date: 03 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.9%). In line with average of industry peers (1.2%).공고 • Apr 09Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022Getinge AB (publ) announced that they will report Q1, 2022 results at 8:00 AM, Central European Standard Time on Apr 26, 2022Reported Earnings • Apr 03Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jan 30+ 5 more updatesGetinge AB to Report Q4, 2022 Results on Feb 01, 2023Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023Reported Earnings • Jan 29Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth.공고 • Jan 29Getinge AB to Report Q1, 2022 Results on Apr 26, 2022Getinge AB announced that they will report Q1, 2022 results on Apr 26, 2022공고 • Dec 24Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million on December 23, 2021. Getinge has paid SEK 596 million for 100% of the equity interest in Talis Clinical LLC on a debt-free basis and subject to customary working capital adjustments. In addition, additional earn-outs may be paid up until 2026 to the extent that the agreed milestone for each earn-out is reached. The purchase price is financed with available cash previously raised in the Swedish Debt Capital Market. Getinge does not expect any material integration costs and the acquisition is not expected to have a material impact on Getinge's earnings in the near term. Getinge AB (OM:GETI B) completed the acquisition of Talis Clinical, LLC on December 23, 2021.Recent Insider Transactions • Dec 17Chief Commercial Officer recently bought €56k worth of stockOn the 15th of December, Carsten Blecker bought around 2k shares on-market at roughly €37.07 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €826k more in shares than they have sold in the last 12 months.Reported Earnings • Oct 21Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr6.31b (down 21% from 3Q 2020). Net income: kr757.0m (down 45% from 3Q 2020). Profit margin: 12% (down from 17% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 18Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr6.59b (down 5.5% from 2Q 2020). Net income: kr798.0m (up 62% from 2Q 2020). Profit margin: 12% (up from 7.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth.공고 • Jul 16Getinge AB Provides Sales Guidance for the Year 2021Getinge AB provided sales guidance for the year 2021. For 2021, the company estimates that sales will strengthen based on 2019's level to a minimum of SEK 27 billion as health care returns to normal capacity. In the long term, the company expects 2%-4% organic annual growth in net sales.공고 • Jun 11Getinge's New Torin Artificial Intelligence Solution Improves Hospital EfficiencyGetinge now introduces Torin with AI in the United States. The company also announced results from a landmark survey of hospital executives and surgeons in the U.S. showing hospitals are taking steps to speed up OR turnover times, hire new staff and require staff to work longer hours to address backlogs. Getinge's Torin software uses artificial intelligence technology that can quickly and seamlessly improve the speed and efficiency of scheduling surgical procedures. The Torin solution was launched in 2020 as a new resource to help with the planning, management and optimization of surgical procedures. Today's introduction of a new suite of advanced functions for Torin, significantly expands capabilities in key areas including predicting surgery times, managing wait lists and data security. The system can produce highly accurate assessments of surgical procedure timing based on a range of variables including surgery type, patient data, relevant devices and staffing. To address scheduling backlogs, the software ranks pending procedures based on clinical and resource parameters, proposes optimized pre-schedules and integrates the process with existing scheduling functionalities.Recent Insider Transactions • Apr 28Chief Commercial Officer recently bought €27k worth of stockOn the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Apr 26Chief Commercial Officer recently bought €27k worth of stockOn the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr6.17b (up 2.3% from 1Q 2020). Net income: kr644.0m (up 138% from 1Q 2020). Profit margin: 10% (up from 4.5% in 1Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Executive Departure • Apr 24Director has left the companyOn the 20th of April, Johan Stern's tenure in the role of Director ended. We don't have any record of a personal shareholding under Johan's name. Johan is the only executive to leave the company over the last 12 months.Upcoming Dividend • Apr 15Upcoming dividend of kr3.00 per shareEligible shareholders must have bought the stock before 21 April 2021. Payment date: 27 April 2021. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.0%).Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr29.8b (up 12% from FY 2019). Net income: kr3.24b (up 165% from FY 2019). Profit margin: 11% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.공고 • Mar 16Getinge AB Proposes Dividend, Payable on April 27, 2021The Board of Getinge AB and the CEO have proposed that a dividend of SEK 3 per share shall be declared. As record date for the dividend, the Board proposed 22 April 2021. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday 27 April 2021.공고 • Feb 18Getinge AB and University of Gothenburg Initiates Strategic Research PartnershipIn a strategic partnership, Getinge will partner up with researchers from the School of Business, Economics and Law at University of Gothenburg, Sweden, on activities related to customer centric innovation and sustainability. Through the partnership, Getinge will gain access to the rearchers' socially relevant and applicable knowledge. During the ongoing pandemic it has become even clearer that quality and efficiency in health care are of utmost importance to society, and that research, innovation and technological progress help meet the challenges of the future. At the same time, the sustainability effects of new technologies and business models must be taken into account. A large and important part of the collaboration is two doctoral student positions where one will study the organization of innovation and the other strategic sustainability. The project organization of innovation will focus on how Getinge can improve processes and organization of activities, where people with different expertise participate, in order to enable innovation of new products and solutions. This includes mobilizing knowledge and coordinating activities and responsibilities within the company as well as with other partners and customers (eg doctors, nurses, hospital technicians). The strategic sustainability project will focus on the companies' attempts to move sustainability activities into the core business. Getinge has recently communicated an ambition to be CO2-neutral in 2025 as a strategic step in being at the forefront of its industry in terms of sustainability work. Important aspects for the doctoral project include how to integrate sustainability into product development and offers to customers.이익 및 매출 성장 예측DB:GTN - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202838,8693,9004,4325,899912/31/202737,0813,4574,0105,3991012/31/202635,1643,0863,8885,317106/30/202634,2362,6763,8065,036N/A3/31/202634,0922,3593,3164,585N/A12/31/202534,9692,2582,6353,949N/A9/30/202535,8542,0543,1374,434N/A6/30/202535,4981,4902,7044,030N/A3/31/202535,5661,4792,4843,798N/A12/31/202434,7591,6383,2684,577N/A9/30/202433,5911,6912,5663,862N/A6/30/202433,3282,5843,2794,593N/A3/31/202432,1992,2853,2634,633N/A12/31/202331,8272,4121,6042,957N/A9/30/202330,4232,2511,3202,654N/A6/30/202329,7562,1541,2522,519N/A3/31/202329,2512,5431,1052,293N/A12/31/202228,2922,4912,2313,367N/A9/30/202227,7812,7072,8353,916N/A6/30/202227,1462,6653,0854,135N/A3/31/202227,0622,8604,1885,173N/A12/31/202127,0492,9705,6306,560N/A9/30/202127,9003,2926,5857,533N/A6/30/202129,5713,9166,8937,811N/A3/31/202129,9553,6127,0217,988N/A12/31/202029,8193,2396,1547,199N/A9/30/202029,4783,0505,2186,336N/A6/30/202027,7381,8784,2395,437N/A3/31/202027,0441,487N/A4,690N/A12/31/201926,5591,222N/A3,832N/A9/30/201925,9511,030N/A2,836N/A6/30/201925,398-632N/A3,082N/A3/31/201924,852-654N/A2,592N/A12/31/201824,172-967N/A2,503N/A9/30/201823,653-727N/A2,899N/A6/30/201822,914847N/A2,371N/A3/31/201822,552676N/A2,193N/A12/31/201722,4951,096N/A2,763N/A9/30/201717,061596N/A3,466N/A6/30/201719,046390N/A3,599N/A3/31/201720,604701N/A3,839N/A12/31/201622,170698N/A3,671N/A9/30/201629,6501,203N/A3,372N/A6/30/201629,6461,462N/A3,369N/A3/31/201629,9001,410N/A3,504N/A12/31/201530,2351,390N/A3,458N/A9/30/201529,3031,429N/A3,366N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GTN 의 연간 예상 수익 증가율(10.4%)이 saving rate(2.1%)보다 높습니다.수익 vs 시장: GTN 의 연간 수익(10.4%)이 German 시장(15.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: GTN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: GTN 의 수익(연간 4.8%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: GTN 의 수익(연간 4.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GTN의 자본 수익률은 3년 후 10.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/11 04:43종가2026/08/11 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Getinge AB (publ)는 24명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierScott BardoBerenbergDelphine Le LouetBernstein21명의 분석가 더 보기
공고 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
공고 • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.
공고 • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.
공고 • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.
공고 • Jul 16Getinge AB Provides Sales Guidance for the Year 2021Getinge AB provided sales guidance for the year 2021. For 2021, the company estimates that sales will strengthen based on 2019's level to a minimum of SEK 27 billion as health care returns to normal capacity. In the long term, the company expects 2%-4% organic annual growth in net sales.
Reported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr3.09 (vs kr1.92 in 2Q 2025)Second quarter 2026 results: EPS: kr3.09 (up from kr1.92 in 2Q 2025). Revenue: kr8.38b (up 1.7% from 2Q 2025). Net income: kr841.0m (up 61% from 2Q 2025). Profit margin: 10.0% (up from 6.4% in 2Q 2025). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.
공고 • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.
Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.
공고 • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.
공고 • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.
공고 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026
공고 • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.
공고 • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.
공고 • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).
공고 • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.
공고 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
공고 • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index
공고 • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.
공고 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025
공고 • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.
공고 • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden
공고 • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.
Recent Insider Transactions • Dec 31Independent Director recently bought €91k worth of stockOn the 23rd of December, Cecilia Wennborg bought around 6k shares on-market at roughly €15.20 per share. This transaction amounted to 48% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €909k. Insiders have collectively bought €2.3m more in shares than they have sold in the last 12 months.
공고 • Dec 10+ 1 more updateGetinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025
공고 • Nov 28Getinge AB (Publ) Announces Changes of the Nomination CommitteeGetinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson.
공고 • Nov 09Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th.
Reported Earnings • Oct 18Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)Third quarter 2024 results: EPS: kr0.007 (down from kr3.28 in 3Q 2023). Revenue: kr7.87b (up 3.5% from 3Q 2023). Net income: kr2.00m (down 100% from 3Q 2023). Profit margin: 0% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Sep 19Independent Director recently bought €98k worth of stockOn the 16th of September, Kristian Samuelsson bought around 5k shares on-market at roughly €19.56 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth €383k. Insiders have collectively bought €1.1m more in shares than they have sold in the last 12 months.
공고 • Sep 13Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled.
Recent Insider Transactions • Sep 05Independent Chairman recently bought €375k worth of stockOn the 3rd of September, Johan Malmquist bought around 20k shares on-market at roughly €18.74 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months.
공고 • Aug 23Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
Reported Earnings • Jul 20Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)Second quarter 2024 results: EPS: kr1.88 (up from kr0.79 in 2Q 2023). Revenue: kr8.31b (up 16% from 2Q 2023). Net income: kr513.0m (up 140% from 2Q 2023). Profit margin: 6.2% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 20% per year.
New Risk • Jul 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.9% average weekly change).
공고 • Jul 01Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €16.30, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.91 per share.
공고 • Apr 23Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024.
Upcoming Dividend • Apr 16Upcoming dividend of kr4.40 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 29 April 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 28Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공고 • Mar 28+ 2 more updatesGetinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025Getinge AB (publ) announced that they will report fiscal year 2024 results on Jan 28, 2025
Declared Dividend • Mar 25Dividend of kr4.40 announcedShareholders will receive a dividend of kr4.40. Ex-date: 23rd April 2024 Payment date: 29th April 2024 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (75% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Mar 16+ 1 more updateGetinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Getinge AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
공고 • Mar 15+ 1 more updateGetinge AB (Publ) Proposes Dividend, Payable on April 29, 2024Getinge AB (publ) at its Annual General Meeting to be held on April 22, 2024, board and the CEO have proposed that a dividend of SEK 4.40 per share shall be declared. As record date for the dividend, the Board proposes April 24, 2024. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting April 29, 2024.
공고 • Mar 08Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.
Reported Earnings • Feb 01Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
공고 • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.
공고 • Jan 23Getinge Announces CFO ChangesLars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge.
Reported Earnings • Oct 23Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr7.61b (up 9.6% from 3Q 2022). Net income: kr894.0m (up 12% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
공고 • Oct 12Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023.
공고 • Sep 20Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023.
Reported Earnings • Jul 19Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr7.18b (up 7.6% from 2Q 2022). Net income: kr214.0m (down 65% from 2Q 2022). Profit margin: 3.0% (down from 9.0% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 7% per year.
공고 • Jul 08Getinge Receives US FDA 510(K) Clearance for Servo-Air® LiteGetinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €17.93, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 9.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.98 per share.
공고 • Jun 01Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023. The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023.
Reported Earnings • Apr 27First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr7.14b (up 16% from 1Q 2022). Net income: kr586.0m (up 9.7% from 1Q 2022). Profit margin: 8.2% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.
Buying Opportunity • Apr 27Now 23% undervaluedOver the last 90 days, the stock is up 9.0%. The fair value is estimated to be €29.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 5.6%.
Upcoming Dividend • Apr 20Upcoming dividend of kr4.25 per share at 1.6% yieldEligible shareholders must have bought the stock before 27 April 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%).
공고 • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.
Reported Earnings • Feb 02Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)Full year 2022 results: EPS: kr9.15 (down from kr10.90 in FY 2021). Revenue: kr28.3b (up 4.6% from FY 2021). Net income: kr2.49b (down 16% from FY 2021). Profit margin: 8.8% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
공고 • Feb 02Getinge AB (Publ) Proposes DividendGetinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00).
Reported Earnings • Oct 21Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr6.94b (up 10% from 3Q 2021). Net income: kr798.0m (up 5.4% from 3Q 2021). Profit margin: 12% (in line with 3Q 2021). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Jul 20Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)Second quarter 2022 results: EPS: kr2.21 (down from kr2.93 in 2Q 2021). Revenue: kr6.67b (up 1.3% from 2Q 2021). Net income: kr603.0m (down 24% from 2Q 2021). Profit margin: 9.0% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €19.62, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 45% over the past three years.
Recent Insider Transactions • May 01Independent Chairman recently bought €281k worth of stockOn the 28th of April, Johan Malmquist bought around 10k shares on-market at roughly €28.06 per share. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Apr 27Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022Getinge AB (publ) announced that In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.00 per share April 28, 2022 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting May 3, 2022.
Upcoming Dividend • Apr 20Upcoming dividend of kr4.00 per shareEligible shareholders must have bought the stock before 27 April 2022. Payment date: 03 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.9%). In line with average of industry peers (1.2%).
공고 • Apr 09Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022Getinge AB (publ) announced that they will report Q1, 2022 results at 8:00 AM, Central European Standard Time on Apr 26, 2022
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jan 30+ 5 more updatesGetinge AB to Report Q4, 2022 Results on Feb 01, 2023Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023
Reported Earnings • Jan 29Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth.
공고 • Jan 29Getinge AB to Report Q1, 2022 Results on Apr 26, 2022Getinge AB announced that they will report Q1, 2022 results on Apr 26, 2022
공고 • Dec 24Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million on December 23, 2021. Getinge has paid SEK 596 million for 100% of the equity interest in Talis Clinical LLC on a debt-free basis and subject to customary working capital adjustments. In addition, additional earn-outs may be paid up until 2026 to the extent that the agreed milestone for each earn-out is reached. The purchase price is financed with available cash previously raised in the Swedish Debt Capital Market. Getinge does not expect any material integration costs and the acquisition is not expected to have a material impact on Getinge's earnings in the near term. Getinge AB (OM:GETI B) completed the acquisition of Talis Clinical, LLC on December 23, 2021.
Recent Insider Transactions • Dec 17Chief Commercial Officer recently bought €56k worth of stockOn the 15th of December, Carsten Blecker bought around 2k shares on-market at roughly €37.07 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €826k more in shares than they have sold in the last 12 months.
Reported Earnings • Oct 21Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr6.31b (down 21% from 3Q 2020). Net income: kr757.0m (down 45% from 3Q 2020). Profit margin: 12% (down from 17% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 18Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr6.59b (down 5.5% from 2Q 2020). Net income: kr798.0m (up 62% from 2Q 2020). Profit margin: 12% (up from 7.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth.
공고 • Jul 16Getinge AB Provides Sales Guidance for the Year 2021Getinge AB provided sales guidance for the year 2021. For 2021, the company estimates that sales will strengthen based on 2019's level to a minimum of SEK 27 billion as health care returns to normal capacity. In the long term, the company expects 2%-4% organic annual growth in net sales.
공고 • Jun 11Getinge's New Torin Artificial Intelligence Solution Improves Hospital EfficiencyGetinge now introduces Torin with AI in the United States. The company also announced results from a landmark survey of hospital executives and surgeons in the U.S. showing hospitals are taking steps to speed up OR turnover times, hire new staff and require staff to work longer hours to address backlogs. Getinge's Torin software uses artificial intelligence technology that can quickly and seamlessly improve the speed and efficiency of scheduling surgical procedures. The Torin solution was launched in 2020 as a new resource to help with the planning, management and optimization of surgical procedures. Today's introduction of a new suite of advanced functions for Torin, significantly expands capabilities in key areas including predicting surgery times, managing wait lists and data security. The system can produce highly accurate assessments of surgical procedure timing based on a range of variables including surgery type, patient data, relevant devices and staffing. To address scheduling backlogs, the software ranks pending procedures based on clinical and resource parameters, proposes optimized pre-schedules and integrates the process with existing scheduling functionalities.
Recent Insider Transactions • Apr 28Chief Commercial Officer recently bought €27k worth of stockOn the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Apr 26Chief Commercial Officer recently bought €27k worth of stockOn the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr6.17b (up 2.3% from 1Q 2020). Net income: kr644.0m (up 138% from 1Q 2020). Profit margin: 10% (up from 4.5% in 1Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Executive Departure • Apr 24Director has left the companyOn the 20th of April, Johan Stern's tenure in the role of Director ended. We don't have any record of a personal shareholding under Johan's name. Johan is the only executive to leave the company over the last 12 months.
Upcoming Dividend • Apr 15Upcoming dividend of kr3.00 per shareEligible shareholders must have bought the stock before 21 April 2021. Payment date: 27 April 2021. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.0%).
Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr29.8b (up 12% from FY 2019). Net income: kr3.24b (up 165% from FY 2019). Profit margin: 11% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
공고 • Mar 16Getinge AB Proposes Dividend, Payable on April 27, 2021The Board of Getinge AB and the CEO have proposed that a dividend of SEK 3 per share shall be declared. As record date for the dividend, the Board proposed 22 April 2021. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday 27 April 2021.
공고 • Feb 18Getinge AB and University of Gothenburg Initiates Strategic Research PartnershipIn a strategic partnership, Getinge will partner up with researchers from the School of Business, Economics and Law at University of Gothenburg, Sweden, on activities related to customer centric innovation and sustainability. Through the partnership, Getinge will gain access to the rearchers' socially relevant and applicable knowledge. During the ongoing pandemic it has become even clearer that quality and efficiency in health care are of utmost importance to society, and that research, innovation and technological progress help meet the challenges of the future. At the same time, the sustainability effects of new technologies and business models must be taken into account. A large and important part of the collaboration is two doctoral student positions where one will study the organization of innovation and the other strategic sustainability. The project organization of innovation will focus on how Getinge can improve processes and organization of activities, where people with different expertise participate, in order to enable innovation of new products and solutions. This includes mobilizing knowledge and coordinating activities and responsibilities within the company as well as with other partners and customers (eg doctors, nurses, hospital technicians). The strategic sustainability project will focus on the companies' attempts to move sustainability activities into the core business. Getinge has recently communicated an ambition to be CO2-neutral in 2025 as a strategic step in being at the forefront of its industry in terms of sustainability work. Important aspects for the doctoral project include how to integrate sustainability into product development and offers to customers.